



Making Science work for you...

Jubilant Organosys Ltd.

Regd.Off: Bhartiagram, Gajraula, Distt. Jyotiba Phoolay Nagar - 244 223 (U.P.)

Q2 FY 2008

Net Sales up
33%

EBIDTA up
60%

PAT up
102%

Unaudited Financial Results for the Quarter and Half year ended 30th September, 2007

[Rs. in Million]

CONSOLIDATED RESULTS					Particulars	JUBILANT ORGANOSYS LTD.				
Quarter Ended September 30 (Unaudited)		Half Year Ended September 30 (Unaudited)		Year Ended March 31 (Audited)		Quarter Ended September 30 (Unaudited)		Half Year Ended September 30 (Unaudited)		Year Ended March 31 (Audited)
2007	2006	2007	2006	2007		2007	2006	2007	2006	2007
3295	2678	6248	5337	11116	Domestic sales & services	3282	2679	6231	5338	11111
3260	2303	6049	4069	8318	International sales	2020	1729	3962	2970	6323
6555	4981	12297	9406	19434	Gross sales	5302	4408	10193	8308	17434
(372)	(322)	(714)	(635)	(1337)	Less: Excise Duty on Sales	(372)	(322)	(714)	(635)	(1337)
6183	4659	11583	8771	18097	Net sales	4930	4086	9479	7673	16097
385	171	1381	215	1234	Other income	310	157	1215	198	968
6568	4830	12964	8986	19331	Total income	5240	4243	10694	7871	17065
5050	3884	9498	7251	15560	Total expenditure	3849	3326	7444	6174	13402
132	(116)	141	(89)	(249)	a) (Increase)/Decrease in stock of manufactured goods	179	(111)	147	(134)	(193)
117	97	243	187	392	b) Cost of trading goods sold	118	83	244	151	366
2057	2060	4355	3805	8160	c) Raw & process materials consumed	1920	1991	4107	3691	7916
466	283	778	511	1133	d) Stores, spares, chemicals, catalyst & packing material consumed	292	237	532	439	961
					e) Manufacturing expenses					
397	347	745	643	1305	- Cost of power & fuel	380	347	718	643	1298
146	138	260	237	533	- Other manufacturing expenses	131	135	239	231	512
1029	545	1723	1016	2149	f) Staff cost	374	240	645	442	975
706	530	1253	941	2137	g) Selling, general & admin. expenses	455	404	812	711	1567
1518	946	3466	1735	3771	Operating profit before interest and depreciation	1391	917	3250	1697	3663
109	37	193	92	195	Interest (Net)	51	35	114	75	151
237	153	431	299	623	Depreciation	143	129	284	253	516
1172	756	2842	1344	2953	Profit before tax	1197	753	2852	1369	2996
76	215	349	354	712	Provision for tax (Including Deferred Tax & Fringe Benefits Tax and net of reversals)	80	211	351	353	681
1096	541	2493	990	2241	Net profit after tax	1117	542	2501	1016	2315
(4)	(3)	(36)	(15)	(39)	Minority Interest	-	-	-	-	-
1100	544	2529	1005	2280	Net profit after Minority Interest	1117	542	2501	1016	2315
143.5	143.1	143.5	143.1	143.5	Paid-up share capital (Face value of the share is Re. 1)	143.5	143.1	143.5	143.1	143.5
				8918	Reserves (excluding revaluation reserve) Earnings per share (Not annualized)					9473
7.67	3.80	17.63	7.03	15.93	Basic (Rs.)	7.79	3.79	17.44	7.11	16.17
6.17	3.06	14.18	5.84	13.02	Diluted (Rs.)	6.26	3.05	14.02	5.91	13.22
					Aggregate of non-promoter shareholding					
69076155	68681002	69076155	68681002	69067310	- Number of shares (Re. 1 each)	69076155	68681002	69076155	68681002	69067310
48.15	48.01	48.15	48.01	48.15	- Percentage of shareholding	48.15	48.01	48.15	48.01	48.15

Notes:

- The company through its wholly owned subsidiary invested Euro 1 million to acquire balance 20% equity interest in Belgium based pharmaceutical companies, namely; Pharmaceuticals Services Incorporate N.V and PSI Supply N.V.
- The company increased its holding in its subsidiary Jubilant First Trust Healthcare Ltd. from 51.85% to 77.90%.
- The company transferred holding in Jubilant Organosys (Shanghai) Ltd, a trading subsidiary, to its wholly owned subsidiary Jubilant Pharma Pte. Ltd., Singapore.
- Under the Employee Stock Option Scheme Plan - 2005, 7375 shares were allotted on exercise of vested options.
- Food Polymer Division has been regrouped into Industrial & Performance Products segment from Pharmaceuticals & Life Science Products & Services.

Place : Noida

Dated : 16th October, 2007

Segment wise Revenue, Results & Capital Employed (under Clause 41 of the Listing Agreement)

[Rs. in Million]

CONSOLIDATED RESULTS					Particulars	JUBILANT ORGANOSYS LTD.				
Quarter Ended September 30 (Unaudited)		Half Year Ended September 30 (Unaudited)		Year Ended March 31 (Audited)		Quarter Ended September 30 (Unaudited)		Half Year Ended September 30 (Unaudited)		Year Ended March 31 (Audited)
2007	2006	2007	2006	2007		2007	2006	2007	2006	2007
3768	2464	6878	4519	9234	Segment revenue					
2795	2524	5434	4901	10228	a. Pharmaceuticals and Life Science Products & Services	2499	1907	4776	3424	7224
6563	4988	12312	9420	19462	Gross sales	5310	4415	10208	8322	17462
8	7	15	14	28	Less : Inter segment revenue	8	7	15	14	28
372	322	714	635	1337	Less : Excise duty on Sales	372	322	714	635	1337
6183	4659	11583	8771	18097	Net sales	4930	4086	9479	7673	16097
3682	2392	6715	4381	8950	a. Pharmaceuticals and Life Science Products & Services	2413	1835	4613	3286	6940
2501	2267	4868	4390	9147	b. Industrial & Performance Products	2517	2251	4866	4387	9157
6183	4659	11583	8771	18097	Total	4930	4086	9479	7673	16097
					Segment results (profit (+) / loss (-) before tax and interest from each segment)					
771	543	1414	931	1765	a. Pharmaceuticals and Life Science Products & Services	798	539	1490	940	1980
472	220	806	488	1065	b. Industrial & Performance Products	472	219	808	487	1069
1243	763	2220	1419	2830	Total	1270	758	2298	1427	3049
109	37	193	92	195	Less : i. Interest	51	35	114	75	151
264	92	346	141	475	ii. Other un-allocable expenditure	264	92	345	141	459
(302)	(122)	(1161)	(158)	(793)	iii. Un-allocable Income	(242)	(122)	(1013)	(158)	(557)
1172	756	2842	1344	2953	Total profit before tax	1197	753	2852	1369	2996
					Capital Employed (Segment assets less Segment liabilities)					
21559	12272	21559	12272	13891	a. Pharmaceuticals and Life Science Products & Services	9858	7925	9858	7925	8960
5792	4536	5792	4536	5723	b. Industrial & Performance Products	5770	4518	5770	4518	5696
27351	16808	27351	16808	19614	Total Capital employed in segments	15628	12443	15628	12443	14656
4138	9260	4138	9260	7508	Add: Un-allocable corporate assets less liabilities	12887	13198	12887	13198	12273
31489	26068	31489	26068	27122	Total capital employed in the company	28515	25641	28515	25641	26929

- Other Income includes exchange gain of Rs.289 million for Q2-FY 2008 (previous year-Q2-FY 2007-Rs.26 million) and for H1-FY2008 of Rs.1168 million (previous year-H1-FY 2007 exchange loss of Rs.20 million) on foreign currency borrowings including Foreign Currency Convertible Bonds.
- Figures for previous period / year have been regrouped / reclassified / restated, wherever considered necessary.
- Information on investors complaints for the quarter (Nos.): Opening Balance - Nil, New -46, Disposals -46, Closing Balance - Nil.
- The above unaudited results which were subjected to limited review by the auditors of the company, were reviewed by the Audit Committee and were taken on record by the Board of Directors at its meeting held on 16th October, 2007

For Jubilant Organosys Ltd.

Shyam S Bhartia
Chairman & Managing Director

visit us at www.jubl.com